Loading company
AngioDynamics, Inc.
ANGO · Nasdaq · ·
Next earnings: October 8, 2026 · before the open
$15.59+0.2%Sep 29 close
- 1M
- -1.6%
- 6M
- +43.4%
- 1Y
- +39.6%
- 5Y
- -35.7%
ANGO · Nasdaq · ·
Next earnings: October 8, 2026 · before the open
$15.59+0.2%Sep 29 close
AngioDynamics, Inc. is scheduled to report next on October 8, 2026, before the open. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending May 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMay 31, 2026 | 3 months toMay 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $86.6M | $80.2M | +8.05% |
| Profit | -$11.4M | -$6.1M | -88.51% |
| Profit per share | -$0.27 | -$0.15 | -80.00% |
| Free Cash Flow | $17M | $18M | -5.52% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our strong fourth quarter capped a year of consistent execution at AngioDynamics,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Inc. AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients. The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from AngioDynamics, Inc.’s Item 2.02 8-K filed July 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
AngioDynamics, Inc. has no earnings call transcript available.